Section Arrow
Quote
FDMT.NASDAQ
- 4D Molecular Therapeutics
Quotes are at least 15-min delayed:2026/01/02 01:35 EST
Regular Hours
Last
 7.5
-0.08 (-1.06%)
Day High 
7.7099 
Prev. Close
7.58 
1-M High
11.81 
Volume 
786.77K 
Bid
7.4
Ask
11.2
Day Low
7.43 
Open
7.57 
1-M Low
7.5517 
Market Cap 
433.08M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 8.6 
20-SMA 9.69 
50-SMA 10.43 
52-W High 12.34 
52-W Low 2.235 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.75/-4.25
Enterprise Value
452.05M
Balance Sheet
Book Value Per Share
6.46
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
37.00K
Operating Revenue Per Share
0.04
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
MREOMereo BioPharma Group plc0.4167+0.0462+12.47%-- 
OTLKOutlook Therapeutics1.58-0.285-15.28%0.58PE
VNDAVanda Pharmaceuticals8.82+1.79+25.46%126.25PE
SLSSELLAS Life Sciences Group3.77+0.46+13.90%-- 
FBLGFibroBiologics0.2249-0.017-7.03%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.